IL277333B2 - VEGF antagonists for use in the treatment of diabetic macular edema - Google Patents

VEGF antagonists for use in the treatment of diabetic macular edema

Info

Publication number
IL277333B2
IL277333B2 IL277333A IL27733320A IL277333B2 IL 277333 B2 IL277333 B2 IL 277333B2 IL 277333 A IL277333 A IL 277333A IL 27733320 A IL27733320 A IL 27733320A IL 277333 B2 IL277333 B2 IL 277333B2
Authority
IL
Israel
Prior art keywords
macular edema
diabetic macular
treating diabetic
vegf antagonists
vegf
Prior art date
Application number
IL277333A
Other languages
English (en)
Hebrew (he)
Other versions
IL277333B1 (en
IL277333A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL277333A publication Critical patent/IL277333A/en
Publication of IL277333B1 publication Critical patent/IL277333B1/en
Publication of IL277333B2 publication Critical patent/IL277333B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL277333A 2018-03-16 2019-03-08 VEGF antagonists for use in the treatment of diabetic macular edema IL277333B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643887P 2018-03-16 2018-03-16
US201962805344P 2019-02-14 2019-02-14
PCT/IB2019/051899 WO2019175727A1 (en) 2018-03-16 2019-03-08 Methods for treating ocular diseases

Publications (3)

Publication Number Publication Date
IL277333A IL277333A (en) 2020-10-29
IL277333B1 IL277333B1 (en) 2025-11-01
IL277333B2 true IL277333B2 (en) 2026-03-01

Family

ID=66049363

Family Applications (2)

Application Number Title Priority Date Filing Date
IL277333A IL277333B2 (en) 2018-03-16 2019-03-08 VEGF antagonists for use in the treatment of diabetic macular edema
IL323849A IL323849A (en) 2018-03-16 2025-10-09 Vegf antagonists for use in treating diabetic macular edema

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323849A IL323849A (en) 2018-03-16 2025-10-09 Vegf antagonists for use in treating diabetic macular edema

Country Status (11)

Country Link
US (1) US20210017266A1 (https=)
EP (1) EP3765083A1 (https=)
JP (3) JP6938796B2 (https=)
KR (2) KR20200131839A (https=)
CN (1) CN111867631A (https=)
AU (2) AU2019235577B2 (https=)
CA (1) CA3091096A1 (https=)
IL (2) IL277333B2 (https=)
MX (1) MX2020009140A (https=)
TW (1) TWI727279B (https=)
WO (1) WO2019175727A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
PE20211602A1 (es) 2018-12-18 2021-08-18 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
CN116195003A (zh) * 2020-09-23 2023-05-30 基因泰克公司 对黄斑水肿患者的注射频率的机器学习预测
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340420A1 (en) * 2014-11-07 2016-11-24 Novartis Ag Stable protein solution formulation containing high concentration of an anti-vegf antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
PE20181363A1 (es) * 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
KR20200131839A (ko) * 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340420A1 (en) * 2014-11-07 2016-11-24 Novartis Ag Stable protein solution formulation containing high concentration of an anti-vegf antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEIER JEFFREY S ET AL,, INTRAVITREAL AFLIBERCEPT FOR DIABETIC MACULAR EDEMA 148-WEEK RESULTS FROM THE VISTA AND VIVID STUDIES, 17 September 2016 (2016-09-17) *
LALLY ET AL.,, VASCULAR ENDOTHELIAL GROWTH FACTOR AND DIABETIC MACULAR EDEMA. SURVEY OF OPHTHALMOLOGY, 26 October 2016 (2016-10-26) *

Also Published As

Publication number Publication date
CA3091096A1 (en) 2019-09-19
JP6938796B2 (ja) 2021-09-22
MX2020009140A (es) 2020-09-28
AU2021286278A1 (en) 2022-01-20
AU2021286278C1 (en) 2024-05-23
AU2021286278B2 (en) 2023-09-14
IL277333B1 (en) 2025-11-01
IL277333A (en) 2020-10-29
JP2021191778A (ja) 2021-12-16
RU2020133816A (ru) 2022-04-18
RU2020133816A3 (https=) 2022-04-18
JP2021509912A (ja) 2021-04-08
US20210017266A1 (en) 2021-01-21
EP3765083A1 (en) 2021-01-20
JP2024042697A (ja) 2024-03-28
CN111867631A (zh) 2020-10-30
TWI727279B (zh) 2021-05-11
KR20260036043A (ko) 2026-03-13
AU2019235577A1 (en) 2020-08-27
AU2019235577B2 (en) 2021-09-30
WO2019175727A1 (en) 2019-09-19
KR20200131839A (ko) 2020-11-24
TW201945027A (zh) 2019-12-01
IL323849A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
IL277333B2 (en) VEGF antagonists for use in the treatment of diabetic macular edema
IL272596A (en) Pridopidine for use in the treatment of ALS
IL264641A (en) Acetyl-leucine for use in the treatment of neurodegenerative diseases
ZA201707852B (en) Compounds for use in treating neuromuscular disorders
IL261548B (en) 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions
EP3347368A4 (en) COMPOUNDS AND FORMULATIONS FOR THE TREATMENT OF EYE DISEASES
EP3332012A4 (en) GLP-1 AND USE THEREOF IN COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES
SI3227675T1 (sl) Antagonisti aktivin-actrii in uporaba za zdravljenje mielodisplastičnega sindroma
IL275238A (en) A liquid compound containing antagonistic VEGF
DK4119569T3 (da) Konjugerede antisense-forbindelser til anvendelse i behandling
SMT202100668T1 (it) Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
PL3288588T3 (pl) Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki
PL3145511T3 (pl) Kompozycja do leczenia oka
EP3383852A4 (en) COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL246855A0 (en) Materials for use in the treatment of retinitis
LT3406258T (lt) Vaistas, skirtas podagros gydymui
EP3737531C0 (en) CROSS BELT SANDER
PL3110425T3 (pl) Trwała kompozycja oftalmiczna przeznaczona zwłaszcza do leczenia zespołu suchego oka
EP3921236C0 (de) Schlauchbeutelmaschine mit dosiervorrichtung
DK3345475T3 (da) Blandemaskine med lateral aflæsningsanordning
GB201615844D0 (en) Agents for use in therapy
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
TH1601001590A (th) เครื่องสำหรับการปฏิบัติกับวัสดุสิ่งทอคล้ายเส้นถัก
GB201617451D0 (en) Polypeptides for use in therapy